Abbott Labs Reports Mixed Q1 Results, Guides In-Line Abbott Laboratories (NYSE:ABT) reported Q1 EPS of 73 cents, ex-items, topping consensus estimates of 70 cents. Revenues in the quarter slipped 0.7% year-over-year to $6.72 billion, and came in short of consensus estimates of $7.06 billion. Abbott said it sees Q2 EPS of 87-89 cents, ex-items, vs. estimates of 88 cents. Meanwhile, the company reaffirmed its guidance for the full fiscal year of 2009, expecting EPS of $3.65-$3.70, vs. estimates of $3.67. Chairman and CEO Miles White said, "Our first-quarter results demonstrate again the value of a well-balanced and highly diverse portfolio of businesses capable of top-tier earnings performance in even the most difficult market conditions. This quarter our collective businesses delivered mid-teens earnings-per-share growth, including continued strong double-digit operational sales growth in global nutritionals, global vascular and international pharmaceuticals. We also saw significant profitability improvements in our vascular and diagnostics segments." http://www.mysmartrend.com/briefs.asp?nwdate=20090415&story=6
Market Data 
Markets 
AI
